{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:38:54Z","timestamp":1788536334992,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571990"],"award-info":[{"award-number":["81571990"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10301404-001-002"],"award-info":[{"award-number":["2018ZX10301404-001-002"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018"],"award-info":[{"award-number":["2018"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.omto.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T01:53:18Z","timestamp":1569894798000},"page":"153-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Yong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2019.09.004_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omto.2019.09.004_bib2","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omto.2019.09.004_bib3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2019.09.004_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"J.\u00a0Hepatocell. Carcinoma"},{"key":"10.1016\/j.omto.2019.09.004_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2019.09.004_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2019.09.004_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2019.09.004_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nrclinonc.2015.106","article-title":"Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma","volume":"12","author":"Killock","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2019.09.004_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic Viruses in Cancer Treatment: A Review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omto.2019.09.004_bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"174","author":"Ribas","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omto.2019.09.004_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fphar.2017.00270","article-title":"Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells","volume":"8","author":"Sanchala","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omto.2019.09.004_bib12","first-page":"303","article-title":"Turning killer into cure -- the story of oncolytic herpes simplex viruses","volume":"20","author":"Zhang","year":"2015","journal-title":"Discov. Med."},{"key":"10.1016\/j.omto.2019.09.004_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-cancerbio-030617-050254","article-title":"Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer","volume":"2","author":"Bommareddy","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.omto.2019.09.004_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.13492","article-title":"Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice","volume":"109","author":"Nakatake","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2019.09.004_bib15","doi-asserted-by":"crossref","first-page":"e01386-18","DOI":"10.1128\/JVI.01386-18","article-title":"A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma","volume":"92","author":"Abdullahi","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.09.004_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1478-3231.2011.02628.x","article-title":"Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer","volume":"31","author":"Argnani","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.omto.2019.09.004_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1525-0016(03)00092-3","article-title":"Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect","volume":"7","author":"Fu","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.cgt.7700558","article-title":"Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection","volume":"10","author":"Jarnagin","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.2013.692","article-title":"The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy","volume":"110","author":"Miao","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2019.09.004_bib20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jgm.1519","article-title":"Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors","volume":"12","author":"Foka","year":"2010","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omto.2019.09.004_bib21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/sj.gt.3300861","article-title":"Hepatoma-specific antitumor activity of an albumin enhancer\/promoter regulated herpes simplex virus in\u00a0vivo","volume":"6","author":"Miyatake","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/mt.2011.265","article-title":"Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells","volume":"20","author":"Fu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.000098","article-title":"Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma","volume":"96","author":"Jebar","year":"2015","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omto.2019.09.004_bib24","doi-asserted-by":"crossref","first-page":"34531","DOI":"10.1038\/srep34531","article-title":"Increasing the Efficiency of CRISPR\/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2019.09.004_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ymthe.2005.07.533","article-title":"The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma","volume":"12","author":"Hummel","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2019.09.004_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2019.09.004_bib28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2019.09.004_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000479573","article-title":"Lenvatinib in Advanced Hepatocellular Carcinoma","volume":"6","author":"Kudo","year":"2017","journal-title":"Liver Cancer"},{"key":"10.1016\/j.omto.2019.09.004_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1743-422X-5-68","article-title":"Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice","volume":"5","author":"Israyelyan","year":"2008","journal-title":"Virol. J."},{"key":"10.1016\/j.omto.2019.09.004_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fonc.2017.00195","article-title":"Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer","volume":"7","author":"Howells","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2019.09.004_bib32","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.gt.3302064","article-title":"Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy","volume":"10","author":"Ahmed","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib33","first-page":"2306","article-title":"Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype","volume":"62","author":"Fu","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2019.09.004_bib34","first-page":"2727","article-title":"Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms","volume":"9","author":"Nakamori","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2019.09.004_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0042-6822(82)90470-6","article-title":"Glycoprotein processing in mutants of HSV-1 that induce cell fusion","volume":"117","author":"Person","year":"1982","journal-title":"Virology"},{"key":"10.1016\/j.omto.2019.09.004_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0042-6822(84)90022-9","article-title":"Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion","volume":"137","author":"Bzik","year":"1984","journal-title":"Virology"},{"key":"10.1016\/j.omto.2019.09.004_bib37","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1128\/JVI.77.12.6836-6844.2003","article-title":"Herpes simplex virus glycoprotein K, but not its syncytial allele, inhibits cell-cell fusion mediated by the four fusogenic glycoproteins, gD, gB, gH, and gL","volume":"77","author":"Avitabile","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.09.004_bib38","doi-asserted-by":"crossref","first-page":"e947872","DOI":"10.4161\/21624011.2014.947872","article-title":"Healing after death: antitumor immunity induced by oncolytic adenoviral therapy","volume":"3","author":"Jiang","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2019.09.004_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.1701021","article-title":"Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies","volume":"200","author":"van Vloten","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2019.09.004_bib41","doi-asserted-by":"crossref","first-page":"e1581528","DOI":"10.1080\/2162402X.2019.1596006","article-title":"Oncolytic viruses: how \u201clytic\u201d must they be for therapeutic efficacy?","volume":"8","author":"Davola","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2019.09.004_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/mt.2013.238","article-title":"Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.09.004_bib43","doi-asserted-by":"crossref","first-page":"805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.omto.2019.09.004_bib44","doi-asserted-by":"crossref","first-page":"102617","DOI":"10.18632\/oncotarget.18309","article-title":"Review: Oncolytic virotherapy, updates and future directions","volume":"8","author":"Fountzilas","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2019.09.004_bib45","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","article-title":"Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes","volume":"24","author":"I\u00f1arrairaegui","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.omto.2019.09.004_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000451016","article-title":"Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials","volume":"92","author":"Kudo","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.omto.2019.09.004_bib47","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2019.09.004_bib48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2019.09.004_bib49","first-page":"19","article-title":"Preparation of HSV-DNA and Production of Infectious Virus","volume":"10","author":"Maclean","year":"1998","journal-title":"Methods Mol. Med."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770519300889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770519300889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:33:57Z","timestamp":1778880837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770519300889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":49,"alternative-id":["S2372770519300889"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2019.09.004","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}